What is the purpose of this trial?
The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR >45ml/min/1.73 m2 who are chronically receiving loop diuretics.
Ages: 18 years and older
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date: 04/19/2017
End Date: 10/31/2018
Last Updated: 02/22/2018
Study HIC#: 2000020019